Skip to Main Content

GSK and CureVac have restructured an ongoing partnership that gives the British pharma giant control over the development of experimental mRNA-based Covid and flu vaccines, the companies said Wednesday.

CureVac, the German biotech that focuses on mRNA vaccines, will receive an initial payment of €400 million upfront ($430 million) from GSK, and is eligible for another €1.05 billion ($1.1 billion) in future payments if certain milestones are hit. In exchange, GSK is taking full control over the development, manufacturing, and marketing of vaccines for seasonal flu and Covid that are currently in Phase 2 trials, and a bird flu vaccine in Phase 1 studies.


All of the vaccines were developed using CureVac’s mRNA technology. The two companies have been working together to develop vaccines for infectious diseases since 2020.

STAT+ Exclusive Story


This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in



Totals $468 per year

$39/month Get Started

Totals $468 per year



for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month



Save 15%

$399/year Get Started

Save 15%

11+ Users


Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users


Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.


STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.